273 related articles for article (PubMed ID: 21199319)
1. Real-world evaluation of health-care resource utilization and costs in employees with fibromyalgia treated with pregabalin or duloxetine.
Harnett J; Margolis J; Cao Z; Fowler R; Sanchez RJ; Mardekian J; Silverman SL
Pain Pract; 2011; 11(3):217-29. PubMed ID: 21199319
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of healthcare resource utilization and costs in employees with pain associated with diabetic peripheral neuropathy treated with pregabalin or duloxetine.
Margolis J; Cao Z; Fowler R; Harnett J; Sanchez RJ; Mardekian J; Silverman SL
J Med Econ; 2010; 13(4):738-47. PubMed ID: 21091395
[TBL] [Abstract][Full Text] [Related]
3. Health care costs in patients with fibromyalgia on pregabalin vs. duloxetine.
Burke JP; Sanchez RJ; Joshi AV; Cappelleri JC; Kulakodlu M; Halpern R
Pain Pract; 2012 Jan; 12(1):14-22. PubMed ID: 21615857
[TBL] [Abstract][Full Text] [Related]
4. Clinical comorbidities, treatment patterns, and healthcare costs among patients with fibromyalgia newly prescribed pregabalin or duloxetine in usual care.
Gore M; Tai KS; Chandran A; Zlateva G; Leslie D
J Med Econ; 2012; 15(1):19-31. PubMed ID: 21970699
[TBL] [Abstract][Full Text] [Related]
5. Health care costs in patients with painful diabetic peripheral neuropathy prescribed pregabalin or duloxetine.
Burke JP; Sanchez RJ; Joshi AV; Cappelleri JC; Kulakodlu M; Halpern R
Pain Pract; 2012 Mar; 12(3):209-18. PubMed ID: 21676163
[TBL] [Abstract][Full Text] [Related]
6. Comparison of medication adherence and healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia.
Zhao Y; Sun P; Watson P; Mitchell B; Swindle R
Pain Pract; 2011; 11(3):204-16. PubMed ID: 20807351
[TBL] [Abstract][Full Text] [Related]
7. Direct medical costs and medication compliance among fibromyalgia patients: duloxetine initiators vs. pregabalin initiators.
Sun P; Peng X; Sun S; Novick D; Faries DE; Andrews JS; Wohlreich MM; Wu A
Pain Pract; 2014 Jan; 14(1):22-31. PubMed ID: 23489659
[TBL] [Abstract][Full Text] [Related]
8. Medication adherence and healthcare costs among patients with diabetic peripheral neuropathic pain initiating duloxetine versus pregabalin.
Zhao Y; Sun P; Watson P
Curr Med Res Opin; 2011 Apr; 27(4):785-92. PubMed ID: 21303196
[TBL] [Abstract][Full Text] [Related]
9. Impact of a step-therapy protocol for pregabalin on healthcare utilization and expenditures in a commercial population.
Udall M; Louder A; Suehs BT; Cappelleri JC; Joshi AV; Patel NC
J Med Econ; 2013; 16(6):784-92. PubMed ID: 23565813
[TBL] [Abstract][Full Text] [Related]
10. Medication dosing patterns associated with duloxetine and pregabalin among patients with fibromyalgia.
Sun P; Zhao Y; Zhao Z; Watson P
Curr Med Res Opin; 2011 Sep; 27(9):1793-801. PubMed ID: 21810060
[TBL] [Abstract][Full Text] [Related]
11. Potential drug-drug and drug-condition interactions among fibromyalgia patients initiating pregabalin or duloxetine: prevalence and health care expenditure impact.
Johnston SS; Udall M; Cappelleri JC; Johnson BH; Shrady G; Chu BC; Silverman SL
Pain Med; 2014 Aug; 15(8):1282-93. PubMed ID: 24401017
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics, pharmacotherapy and healthcare resource use among patients with fibromyalgia newly prescribed gabapentin or pregabalin.
Gore M; Sadosky AB; Zlateva G; Clauw DJ
Pain Pract; 2009; 9(5):363-74. PubMed ID: 19500273
[TBL] [Abstract][Full Text] [Related]
13. Retrospective evaluation of clinical characteristics, pharmacotherapy and healthcare resource use among patients prescribed pregabalin or duloxetine for diabetic peripheral neuropathy in usual care.
Gore M; Zlateva G; Tai KS; Chandran AB; Leslie D
Pain Pract; 2011; 11(2):167-79. PubMed ID: 20723096
[TBL] [Abstract][Full Text] [Related]
14. Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy.
Udall M; Harnett J; Mardekian J
J Med Econ; 2012; 15(2):361-70. PubMed ID: 22181052
[TBL] [Abstract][Full Text] [Related]
15. Initial use of pregabalin, patterns of pain-related pharmacotherapy, and healthcare resource use among older patients with fibromyalgia.
Gore M; Sadosky A; Zlateva G; Clauw D
Am J Manag Care; 2010 May; 16(5 Suppl):S144-53. PubMed ID: 20586523
[TBL] [Abstract][Full Text] [Related]
16. Estimating the economic benefits of positive shifts in fibromyalgia severity: an exploratory analysis based on modeling of clinical trial data of pregabalin.
Cappelleri JC; Bushmakin AG; Zlateva G; Chandran A
J Med Econ; 2013; 16(1):55-61. PubMed ID: 22954060
[TBL] [Abstract][Full Text] [Related]
17. Health outcomes and costs among employees with fibromyalgia treated with pregabalin vs. standard of care.
Kleinman NL; Sanchez RJ; Lynch WD; Cappelleri JC; Beren IA; Joshi AV
Pain Pract; 2011; 11(6):540-51. PubMed ID: 21392253
[TBL] [Abstract][Full Text] [Related]
18. Identification of patients with painful diabetic peripheral neuropathy who have a favorable cost profile with pregabalin treatment.
Udall M; Mardekian J; Cabrera J
Pain Pract; 2013 Jul; 13(6):476-84. PubMed ID: 23150918
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics, pharmacotherapy, and healthcare resource use among patients with fibromyalgia newly prescribed pregabalin or tricyclic antidepressants.
Gore M; Tai KS; Chandran A; Zlateva G; Leslie D
J Med Econ; 2012; 15(1):32-44. PubMed ID: 21970698
[TBL] [Abstract][Full Text] [Related]
20. Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans.
Margolis JM; Cao Z; Onukwugha E; Sanchez RJ; Alvir J; Joshi AV; Mullins CD
Am J Manag Care; 2010 Jun; 16(6):447-56. PubMed ID: 20560688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
